II. Legumes

II. 6 Soybean

King of the isoflavone matrix – complete plant protein, phytoestrogen, and equol precursor in a single bean.

Latin: Glycine max (L.) Merr. (Fabaceae)

" evidence="★ ★ ★ (human RCT meta-analyses – cholesterol, bone, menopause)" microbiota="isoflavones → substrate for equol-converting microbiome (Adlercreutzia, Slackia, Eggerthella)"]

Soybean in 1 minute

What does it provide? Complete plant protein (≈ 36 g/100 g dry – the only legume containing all essential amino acids in optimal ratios, PDCAAS = 1.0), isoflavones (genistein, daidzein, glycitein – ≈ 100–200 mg/100 g dry, phytoestrogen), lecithin (phosphatidylcholine source), calcium (≈ 277 mg/100 g dry), and vitamin K2 precursor (in fermented forms). Gut bacteria convert isoflavone glycosides to aglycones, and some (about 25–50% of the population) further to equol – the most potent estrogen-receptor-beta agonist [2789].

How much? Weekly 3–5×, 80–120 g tofu/tempeh, 200–250 ml soy milk, or ½ cup cooked soybeans per serving. In menopausal RCTs, 50–100 mg isoflavone/day (≈ 100 g tofu or 250 ml soy milk) reduces hot flashes and mitigates osteoporosis.

When to avoid? Soy allergy (one of the most common in childhood), active estrogen-dependent cancer (breast cancer – disputed, see Myths), hypothyroidism on unstable levothyroxine dose (absorption interference – ≥ 4 hour separation), severe kidney stones (moderate oxalate), warfarin (vitamin K), infant (soy formula only if indicated), GMO sensitivity may prefer organically grown soy.

📜 Historical Overview

Soybean is an ancient East Asian domesticate – cultivation began in China around the 11th century BCE, and it became one of the "wu gu" (five sacred grains) by the Han dynasty. Early records suggest Chinese monks discovered tofu-making in the 2nd century BCE, when they accidentally coagulated soy milk with sea salt (nigari, calcium-magnesium chloride). Tempeh was born on the Indonesian island of Java in the 17th–18th century, via Rhizopus oligosporus fungal fermentation. Soy arrived in Europe in the 17th century – brought back from Japan by German traveler Engelbert Kaempfer. From the mid-20th century, the USA became the world's largest soy producer; today about 80% of global production is GMO soy, mostly for feed and the oil industry. For human consumption, fermented forms (tempeh, miso, natto) and tofu/soy milk dominate.

Scientific Background

Soybean offers four clinically documented bioactive groups. (1) Complete plant protein: PDCAAS = 1.0 (the highest plant value), methionine slightly limiting, but practically every essential amino acid is covered. Sacks et al. (2006) Circulation AHA position: daily 25 g soy protein gives ≈ 3–4% LDL reduction [2787].

(2) Isoflavones (genistein, daidzein, glycitein): phytoestrogens with selective estrogen-receptor-beta affinity. Gut bacteria hydrolyze isoflavone glycosides to aglycones, then about 25–50% of the population (equol-producer metabotype, mainly Asian populations) converts some daidzein to S-equol – the most potent ER-β agonist. Equol-converting taxa include Adlercreutzia equolifaciens, Slackia isoflavoniconvertens, Eggerthella spp. (Setchell 2010 J Nutr) [2719]. Clinically, a meta-analysis of menopausal hot-flash trials (Taku 2012 Menopause) showed significant symptom reduction at 50–100 mg isoflavone intake/day [2786]; for bone, Wei (2012 Asian Pac J Trop Med) reports improvement in lumbar spine BMD in postmenopausal women [2788].

(3) Lecithin and phospholipids: phosphatidylcholine source, liver and cognitive support (limited clinical evidence).

(4) Anti-nutrients and prebiotic fiber: soybean contains phytate (≈ 1–1.5 g/100 g), trypsin inhibitors (inactivated by heat treatment), and GOSs (raffinose, stachyose – Bifidobacterium substrate, but gas-forming in IBS-sensitive individuals).

At the microbiome level, soy isoflavone conversion is individual – the "equol-producer" microbiome phenotype yields 5–10× greater clinical effect from the same soy intake than the non-producer. Regular soy consumption may increase the share of converter taxa.

✅ Combine with

+ Fermented forms (tempeh, miso, natto): partly pre-converted isoflavone aglycone → better bioavailability, microbiome synergy.
+ Whole grain (brown rice, buckwheat, millet): classic Asian pattern, complementary amino acid profile + broader fiber spectrum.
+ Sea vegetable (nori, wakame): iodine supplement against goitrogen concern.
+ Small portion of fermented dairy or kefir (as separate meal): microbiome diversity supports equol conversion.
+ Soaking + cooking (anti-nutrient reduction): phytate and trypsin inhibitor are significantly reduced.
+ Olive oil, sesame oil: fat for fat-soluble vitamins.

🚫 Avoid combining with

Levothyroxine (Euthyrox) simultaneous intake: soy reduces hormone absorption – keep > 4 hours apart.
Raw or insufficiently cooked soybean: trypsin inhibitors and lectins – GI irritation. Minimum 30+ minutes of boiling or pressure cooking.
Iron supplement in the same time window: phytate chelation – separate by ≥ 2 hours.

⚠️ When to avoid – condition-specific

Soy allergy: strict avoidance (one of the seven most common childhood allergens).
Hypothyroidism with unstable thyroid hormone replacement: safe at a stable dose, but time separation is critical.
Estrogen-dependent cancers (breast cancer) during active treatment: approach conservatively – several newer meta-analyses (Chen 2014, Wu 2008) show moderate soy intake does NOT raise risk, and in Asian populations is protective [1691] [1708]; daidzein does not impair tamoxifen efficacy. Individual oncology consultation recommended.
Kidney stones (moderate oxalate) and CKD 3–5: dose control.
IBS elimination phase: whole soybean is high FODMAP – avoid, but tofu/tempeh tolerable.
Infant: soy formula only if indicated, medical supervision required due to phytoestrogen concern.

❌ Myths and their refutation

"Soy increases breast cancer risk."Myth. The 1990s theoretical concern was refuted by 2008–2014 meta-analyses (Wu 2008, Chen 2014): moderate soy consumption (10–25 g soy protein/day) does NOT raise breast cancer risk, and in Asian populations is protective – and is safe alongside tamoxifen therapy. The "phytoestrogen = estrogen mimetic" simplification is mistaken: due to SERM-like, tissue-selective receptor affinity, the tissue effect is tissue-specific and often estrogen-antagonist.

"Soy 'feminizes' men."Myth. The Hamilton-Reeves (2010 Fertil Steril 94(3):997–1007) meta-analysis showed NO serum testosterone or estradiol change in men from soy consumption [1635]. Anecdotal "soy → gynecomastia" case reports involve kg-amount daily soy intake – at normal dietary doses, safe.

"Non-fermented soy is toxic."Myth. Tofu, soy milk, and edamame have been the daily food of billions in Asia for millennia. Fermented forms (tempeh, miso, natto) have ADVANTAGES (reduced phytate, higher K2, microbiome synergy), but non-fermented soy is not toxic.

"Soy is thyroid-suppressing."Partly myth. Soy is a mild goitrogen alongside an iodine-deficient diet, but with normal iodine supply (iodized salt, seafood), the clinical effect is negligible. However, levothyroxine absorption reduction is validated – time separation is needed.

References

[1635] Hamilton-Reeves JM et al. Clinical studies show no effects of soy protein or isoflavones on reproductive hormones in men: results of a meta-analysis2010;94(3):997–1007. Fertil Steril. Link

Fertil Steril meta-analysis of clinical studies examining the effects of soy protein or isoflavones on reproductive hormones in men.

[1691] Chen M, Rao Y, Zheng Y, et al. Association between soy isoflavone intake and breast cancer risk for pre- and post-menopausal women: a meta-analysis of epidemiological studies2014;9(2):e89288. PLoS One. Link

BACKGROUND: Conclusions drawn from meta-analyses on the association between soy isoflavone intake and breast cancer risk for pre- and post-menopausal women are not fully consistent. These meta-analyses did not explore the influence of different study designs on the pooled results on the basis of distinguishing between pre- and post-menopausal women. METHODOLOGY AND PRINCIPAL FINDINGS: We performed a meta-analysis of 35 studies which reported results of association between soy isoflavone intake and breast cancer risk for pre- and/or post-menopausal women, calculated pooled odds ratios and their 95\% confidence intervals of pre- and post-menopausal women respectively, and further explored soy isoflavone-breast cancer association on the basis of considering different study regions and designs. Summary results suggested that soy isoflavone intake has a protective effect against breast cancer for both pre- and post-menopausal women. However, they are influenced by study design and region. Pooled ORs of studies carried out in Asian countries suggested that soy isoflavone's protective effect exist in both pre- and post-menopausal women (OR = 0.59, 95\%CI: 0.48-0.69 for premenopausal women; OR = 0.59, 95\%CI: 0.44-0.74 for postmenopausal women).

[1708] Wu AH, Yu MC, Tseng CC, Pike MC. Epidemiology of soy exposures and breast cancer risk2008;98(1):9–14. Br J Cancer. Link

Most of the early studies published on soy and breast cancer were not designed to test the effect of soy; the assessment of soy intake was usually crude and few potential confounders were considered in the analysis. In this review, we focused on studies with relatively complete assessment of dietary soy exposure in the targeted populations and appropriate consideration for potential confounders in the statistical analysis of study data. Meta-analysis of the 8 (1 cohort, 7 case-control) studies conducted in high-soy-consuming Asians show a significant trend of decreasing risk with increasing soy food intake. Compared to the lowest level of soy food intake (or=20 mg isoflavones per day). In contrast, soy intake was unrelated to breast cancer risk in studies conducted in the 11 low-soy-consuming Western populations whose average highest and lowest soy isoflavone intake levels were around 0.8 and 0.15 mg per day, respectively. Thus, the evidence to date, based largely on case-control studies, suggest that soy food intake in the amount consumed in Asian populations may have protective effects against breast cancer.

[2719] Setchell KDR, Clerici C. Equol: history, chemistry, and formation. The Journal of Nutrition. 2010. Link

Review of equol, a metabolite formed by gut bacteria from soy's daidzein isoflavone. Only about 25–30% of the population are "equol producers" — i.e., harbor the appropriate gut bacteria — which may explain why studies of soy's health effects are contradictory. Equol-producer status is a microbiota-dependent metabotype and an early, well-documented example of personalized nutrition.

[2786] Taku K, Melby MK, Kronenberg F, Kurzer MS, Messina M. Extracted or synthesized soybean isoflavones reduce menopausal hot flash frequency and severity: systematic review and meta-analysis of randomized controlled trials. Menopause. 2012. Link

Meta-analysis of randomized controlled trials showing that extracted or synthesized soy isoflavones reduce menopausal hot flash frequency and severity. It supports the climacteric symptom-reducing effect of isoflavone intake.

[2787] Sacks FM, Lichtenstein A, Van Horn L, Harris W, Kris-Etherton P, Winston M. Soy protein, isoflavones, and cardiovascular health: an American Heart Association science advisory. Circulation. 2006. Link

American Heart Association science advisory on soy protein, isoflavones, and cardiovascular health. It reviews the modest LDL-cholesterol-lowering effect of soy protein and the limited independent cardiovascular contribution of isoflavones.

[2788] Wei P, Liu M, Chen Y, Chen DC. Systematic review of soy isoflavone supplements on osteoporosis in women. Asian Pacific Journal of Tropical Medicine. 2012. Link

Systematic review of soy isoflavone supplements on osteoporosis in women. It suggests that isoflavone intake may improve lumbar spine bone mineral density in postmenopausal women.

[2789] . Soybeans, mature seeds. USDA FoodData Central. 2019. Link

Entry from the USDA FoodData Central nutrition database for mature soybeans, documenting macro- and micronutrient composition (including protein, calcium, phytate). A reference source for the nutrient values reported in the chapter.

[2790] . Soy products — FODMAP serving guidance. Monash University FODMAP. 2023. Link

Classification from the Monash University FODMAP database for soy products: whole cooked soybeans are high FODMAP due to GOS, while tofu and tempeh are low FODMAP in small servings. It provides a practical basis for IBS-friendly portioning.